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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S302gel was contained within the knee while slowly degrading over a period
of 4 weeks. Group 2: No changes in patellar cartilage quantity or quality
occurred following intra-articular gel injection (p>0.10). At t¼0;
t¼6weeks and t¼12weeks, cartilage volume L/R ratios were 1.020.12;
0.990.1; 1.08.04 respectively; for attenuation 1.040.09; 1.050.08;
1.030.13. Histology conﬁrmed that the gel did not affect the cartilage.
Group 3; sustained drug release from the gel was conﬁrmed with Cel-
ecoxib being detectable in plasma samples up to 40 days at a sustained
level of w50-100 ìg/l (ﬁgure 2).
Conclusions: Aliphatically-modiﬁed PCLA-PEG-PCLA form radiopaque
and biocompatible gels which are able to deliver encapsulated drugs
upon degradation over a period of several weeks. This system is
therefore a promising candidate for intra articular drug delivery as
a treatment for OA.
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SAFETY OF MULTIPLE MUSCULOSKELETAL INJECTIONS IN PATIENTS
TAKING WARFARIN OR WARFARIN AND ASPIRIN
S.P. Pandit y, J. Waterman z, J. Corriea x. yUniv. of Connecticut Hlth.Ctr.,
Farmington, CT, USA; zUniv. of Connecticut Sch. of Med. and the
Connecticut VA Hlth.care System, Farmington and Newington, CT, USA;
x The Connecticut VA Hlth.care System, Newington, CT, USA
Purpose: Injections involving the musculoskeletal system are
a common practice in rheumatology. Several studies have shown the
relative safety of single musculoskeletal injections (MSI) in patients
taking warfarin. This prospective study looked at repeated injections
regarding the ongoing safety of MSI in patients taking warfarin and also
in patients taking warfarin and low dose aspirin.
Methods: A total of 42 patients were entered into the study from 1/
2008 to 12/2010. There were a total of 216 injections. All patients who
had at least 2 MSI in any part of their musculoskeletal system and were
actively followed in the VA Anticoagulation Clinic were included in the
study. Patients who received only one MSI or had multiple injectionsbut were not followed by the VA Anticoagulation Clinic during the study
period were excluded. All of the patients were taking warfarin and 14
were also taking aspirin for a variety of causes. All patients were on
stable doses of warfarin and had INR levels within a month of the
injections. After receiving injections, all patients were contacted by
phone within a month of the injections, at the time of the INR check,
and directly asked if there had been any complications related to the
injections.
Results: Of the 216 injections in the 42 patients, the knee was the most
common joint injected (n¼ 91: 42.1%). Other sites of injections included
the shoulder (n ¼ 56: 25.9%); humeral epicondyle (n ¼ 6: 2.7%); small
hand joints (n ¼ 11: 5.1%); wrist (n ¼ 5: 2.3%); various bursae (n ¼ 14:
6.5%); other soft tissue sites (n ¼ 33: 15.2%) Injectates included corti-
costeroids (CS) and hyaluronate. CS injections were the most common
representing 81.8% of the total injections .The average total number of
injections per patient was 5.1. The mode was 2. INR levels ranged from
1.1 - 4.8; average INR: 2.5. Only two patients reported bruising at the
injection site. One patient was also taking aspirin. INRs in both patients
were 2.1 and 2.4. No other complications were reported and no added
complications in the patients taking both warfarin and aspirin.
Conclusions: It has been shown that single MSI are safe in patients on
warfarin. This study demonstrates that repeated injections in any site in
the musculoskeletal system are also safe in patients on warfarin and
patients on warfarin and aspirin.590
AN INNOVATIVE HYALURONIC ACID PRODUCT FOR
VISCOSUPPLEMENTATION IN PATIENTS WITH OSTEOARTHRITIS
S. Gavard. Anteis, Meyrin, Switzerland
Purpose: The speciﬁc formulation [HA+sorbitol] of Synolis V-A is
based on a high molecular weight of HA (> 2 MDa in the ﬁnal sterilized
gel) from non animal origin, with a high HA concentration (20 mg/ml),
combined with a high concentration of a free radical scavenger, the
sorbitol (40 mg/ml). The aims of this study are to evaluate the
mechanical/rheological properties and the resistance to free radicals
degradation of Synolis V-A.
Methods: The rheological properties are analyzed by frequency sweep
experiments at 25C thanks to a parallel plate rheometer (AR2000, TA
Instruments). The resistance to free radical degradation is observed
visually by adding an oxidant agent (H2O2) on the viscosupplement
(Weight of H2O2 ¼ 1/15 x Weight of viscosupplement), by heating the
mixing at 60C and by watching the ﬂow of the product over time. The
resistance to free radical degradation is also followed thanks to an
AR2000 rheometer (time sweep experiments at 37C). Results of
resistance to degradation obtained with Synolis V-A are compared to 5
other commercial viscosupplements.
Results: Visco-elastic properties of Synolis V-A. Synolis V-A is charac-
terized by a visco-elastic behavior close to the human synovial ﬂuid
(viscous and elastic moduli crossing at 0.4 Hz) and high viscous and
elastic moduli due to the high afﬁnity between HA and sorbitol that
stabilizes the structure through a very dense network of hydrogen
bonds. Resistance to free radical degradation. In presence of free radi-
cals (H2O2), Synolis V-A demonstrates a much higher resistance against
free radicals than the other commercial viscosupplements as shown by
the visual observation and by the rheological properties.
Conclusions: Synolis V-A is an innovative viscosupplement made of
hyaluronic acid and sorbitol. Due to its patented formulation and
manufacturing process, Synolis V-A has outstanding rheological prop-
erties and a high resistance against in vivo degradation in the joint. As
demonstrated by several experiments, Synolis V-A is characterized by
a visco-elastic behaviour close to the human synovial ﬂuid, a very high
elasticity and viscosity and a high resistance to free radical degradation.
The synergetic combination of HA of high molecular weight and
sorbitol, combined with a speciﬁc manufacturing process which
included a ﬁnal moist heat sterilization, allows to obtain unique prop-
erties. Moreover, due to the high afﬁnity between HA and sorbitol,
Synolis V-A is stabilized through a very dense network of hydrogen
bonds. This complex structure of gel presents remarkably high visco-
elastic properties. Consequently, thanks to these particular visco-elastic
properties, Synolis V-A has a high ability to lubricate joints and to
absorb shocks, as with a healthy synovial ﬂuid. On the other hand, the
high ability of sorbitol to scavenge and neutralize free radicals (¼
antioxidant effect) allows to limit the degradation of the gel in order to
increase the half-life of the product in the joint (as described in the
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S303literature, free radical degradation is an important factor of HA degra-
dation in the joint and is a key factor of the OA (free radicals is asso-
ciated with chondrocyte death and cartilage destruction).
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591ĂMATERIAL ON THE BASIS OF HYALURONIC ACID FOR SYNOVIAL
FLUID VISCOSUPPLEMENTATION WITH IMPROVED VISCOELASTIC
PROPERTIES AND IN-VIVO BIOSTABILITY
L. Wolfova y, J. Bystronová y, M. Pravda y, J. Matonohová z,
J. Nováková y, V. Velebný x. yContipro Biotech, Dolní Dobrouc, Czech
Republic; zContipro Pharma, Dolní Dobrouc, Czech Republic; xContipro
Group, Dolní Dobrouc, Czech Republic
Purpose: Synovial ﬂuid is a joint lubricant and plays an important role in
cartilage deformation caused by mechanical load. The main component
of synovial ﬂuid is hyaluronic acid with an approximate concentration of
2,5mg/ml and the averagemolecularweight of 3-5MDa in healthy joints.
It is known, that in osteoarthritis the concentration and the average
molecular weight of HA in synovial ﬂuid are signiﬁcantly reduced. This
has a negative effect on the viscoelasticity of the synovial ﬂuid, which
leads to signiﬁcant decrease of the mechanical protection of the articular
system. Also, the articular cartilage function deteriorates. It is also known
that preparations for medical treatment with smaller average molecular
weight have not sufﬁcient viscoelastic properties and undergo biodeg-
radation too quickly. In our previous work we designed a new HAtyramine derivative containing an alkyl‑based linker for the preparation
of non-cytotoxic and biocompatible hydrogel‑based materials with
enhanced mechanical properties. In this work this HA derivative was
further optimized to become a material with suitable properties for
synovial ﬂuid viscosupplementation. For this purpose, partially cross-
linked solutions of this HA derivate were tested.
Methods: In this study partially crosslinked solutions on the basis of the
HAderivatementioned abovewere designed.We studied the inﬂuence of
crosslinked density, HA derivativemolecularweight and concentration of
these solutions in order to optimize the viscoelasticity and to reach the
appropriate properties correspondingwith synovialﬂuid. The viscoelastic
propertiesweremeasured by dynamicmechanical analysis in a frequency
sweep oscillation mode (frequency 0,1-10 Hz at 0,5% strain) and by
determination of storage modulus G0, loss modulus G00 and loss angle d.
Results:
Fig.1:Representative resultsobtainedfromDynamicmechanicalanalysis ina frequency
sweep oscillationmode (frequency 0,1-10 Hz at 0,5% strain) of selected samples
Conclusions: The results obtained so far showed that we can design
and prepare HA‑based materials with suitable properties for synovial
ﬂuid viscosupplementation. Thanks to the partial crosslinking of the HA
solutions we are also able to design materials with enhanced visco-
elastic properties and prolonged biostability compared to HA‑based
treatment preparations with insufﬁcient molecular weight.
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NANOPARTICLE SYSTEM FOR THE LOCAL DELIVERY OF DISEASE
MODIFYING OSTEOARTHRITIC DRUGS
P.C. Periyasamy, J.W. Wennink, R. Wang, M. Karperien, P.J. Dijkstra, J.N.
Post. MIRA Inst. for BioMed. technology and technical medicine, Enschede,
The Netherlands
Purpose: The purpose of this study is to develop the nanoparticles that
i) can be injected intra-articularly ii) target to cartilage due to an
opposite charge difference with the extracellular cartilaginous matrix
and iii) due to their small size can penetrate into the cartilage. In this
way retention time in the joint can be prolonged. By releasing disease
modifying OA drugs (DMOAD) in the vicinity of chondrocytes such
materials may be beneﬁcial for restoring cartilage tissue homeostasis.
Here we demonstrate the generation of drug-containing nanoparticles
for intra-articular joint therapy.
Methods: We have prepared nanoparticles of biodegradable poly
ethylene glycol- poly lactic acid PEG-PLA co-block polymers. The
hydrophilic PEG and hydrophobic PLA ends of this polymer make it
possible to generate micelles that contain drugs. The polymers are
functionalized with UV-sensitive acrylate groups that can be stabilized
by UV-crosslinking. These drug containing nanoparticles will be used
for intra-articular joint injection and release of DMOADs. We have also
established co-culture systems in vitro using MSCs and chondrocytes
where the effect of these molecules and nanocarriers can be tested.
Results: Micelle type nanoparticles using PEG-PLA co-block polymers
were prepared. The obtained dexamethasone loaded nanoparticles had
diameters of 20-80 nm. These nanoparticles are photo-crosslinked at
their hydrophobic cores which provides stability to the structure and
resulted in a slight decrease in average particle size . Dexamethasone
was successfully encapsulated in these nanoparticles. The current
release proﬁles show initial burst release in the ﬁrst 8 hours followed by
a sustained release over at least 3 days.
